logo

For the Inventor, By the Inventor

Provo, UT, United States of America

Kim Leslie O'Neill

This inventor holds 13 USPTO granted patents and 7 published patent applications. Top assignees: Thunder Biotech Inc., Brigham Young University, Other. Active years: 1997-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kim Leslie O'Neill. Retrieved from https://idiyas.com/inventor/kim-leslie-o-neill

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 13 

% Patents Active = 76.9

Average Co-Inventor Count = 1.6

ph-index = 4

Forward Citations = 50(Granted Patents)


Location History:

  • Orem, UT (US) (1997)
  • Provo, UT (US) (2007 - 2024)

Company Filing History:

goldMedal4 out of 4 
 
Thunder Biotech Inc.
 patents
silverMedal3 out of 480 
 
Brigham Young University
 patents
bronzeMedal5 out of 834,570 
Other
 patents
where one patent can have more than one assignee

Years Active: 1997-2024

Loading Chart...
13 patents (USPTO):Explore Patents
1. 12076378 - Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors (2024-09-03),
2. 12024719 - Transgenic macrophages, chimeric antigen receptors, and associated methods (2024-07-02),
3. 11352439 - Macrophage CAR (MOTO-CAR) in immunotherapy (2022-06-07),
4. 11052138 - Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors (2021-07-06),
5. 10889803 - Transgenic macrophages, chimeric antigen receptors, and associated methods (2021-01-12),
6. 10828355 - Use of car and bite technology coupled with an ScFv from an antibody against human thymidine kinase 1 to specifically target tumors (2020-11-10),
7. 10821162 - Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors (2020-11-03),
8. 10434153 - Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors (2019-10-08),
9. 10415017 - Transgenic macrophages, chimeric antigen receptors, and associated methods (2019-09-17),
10. 9267948 - Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof (2016-02-23),
11. 7837998 - Anti-cancer activity of an anti-thymidine kinase monoclonal antibody (2010-11-23),
12. 7311906 - Anti-viral activity of an anti-thymidine kinase monoclonal antibody (2007-12-25),
13. 5698409 - Monoclonal antibodies to thymidine kinase 1 and uses in diagnostic and (1997-12-16),

Title: Innovations by Kim Leslie O'Neill in Tumor Targeting Technologies

Introduction

Kim Leslie O'Neill, an inventive mind located in Provo, UT, has made significant contributions to the field of cancer treatment through his groundbreaking inventions. With an impressive portfolio of 13 patents, O'Neill's work focuses on advanced biotechnologies aimed at specifically targeting tumors using modified cellular approaches.

Latest Patents

Among his latest patents, one highlights the use of car and bite technology combined with a single-chain variable fragment (scFv) derived from an antibody against human thymidine kinase 1. This innovative approach allows for the targeting of tumors by producing modified T-cells that have specific paratopes against human TK1 epitopes. His work involves creating chimeric antigen receptors (CARs) through the fusion of scFv from monoclonal antibodies with T-cell signaling domains, followed by transduction into T-cells to enhance their tumor-targeting capabilities.

Another notable patent describes transgenic macrophages with chimeric antigen receptors. The chimeric receptors include vital components such as a cytoplasmic domain that, upon activation, can polarize a macrophage into beneficial inflammatory states. When a ligand binds to the extracellular domain of these receptors, it activates the intracellular portion, further influencing the macrophage's functionality toward either M1 or M2 polarization.

Career Highlights

Kim Leslie O'Neill has worked with prominent companies like Thunder Biotech Inc. to develop and implement innovative solutions in the biomedical field. His extensive experience and inventive prowess have enabled him to contribute meaningfully to advancements in cancer therapies and immune system engineering.

Collaborations

Throughout his career, O'Neill has collaborated with individuals such as Scott Weber and Nathaniel Lallatin. Their collective expertise in biotechnology has fostered a dynamic environment for creativity and the development of cutting-edge technologies aimed at better therapeutic strategies.

Conclusion

Kim Leslie O'Neill continues to be a pivotal figure in the innovation landscape, particularly in the realm of oncology and immune modulation. His dedication to developing targeted therapies not only exemplifies his talent as an inventor but also signifies a hopeful future for cancer treatment and patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…